INJECTION MEDICINAL FORMULATION FOR TREATMENT AND PROPHYLAXIS OF BLOOD-PARASITIC AND INVASION DISEASES

FIELD: veterinary medicine, pharmacology. ^ SUBSTANCE: invention represents injection antiparasitic medicinal agent containing diminazene salts as an active substance and can be used in treatment and prophylaxis of parasitic diseases. Injection medicinal formulation used for treatment and prophylaxi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SIDORKIN VLADIMIR ALEKSANDROVICH, PRISTENSKIJ DMITRIJ VLADIMIROVICH, SEMENOV SERGEJ VJACHESLAVOVICH, STAROVEROV SERGEJ ALEKSANDROVICH, ERMILOV DMITRIJ NIKOLAEVICH
Format: Patent
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:FIELD: veterinary medicine, pharmacology. ^ SUBSTANCE: invention represents injection antiparasitic medicinal agent containing diminazene salts as an active substance and can be used in treatment and prophylaxis of parasitic diseases. Injection medicinal formulation used for treatment and prophylaxis of blood-parasitic and invasion diseases and comprising diminazene as an active substance, organic solvent, stabilizing agent and preserving agent involves additionally a surface-active substance as a solubilizing agent and distilled water as a co-solvent and wherein poly-(1-vinyl-2-pyrrolidone) is used as a stabilizing agent wherein components are taken in the following content, wt.-%: active substance, 1-20; organic solvent, 10-50; co-solubilizing agent, 1-20; stabilizing agent, 1-20; preserving agent, 0.01-1, and co-solvent, up to 100. Proposed medicinal formulation comprises diminazene benzoate or diminazene adipate, or diminazene nicotinate as an active substance. "Cremofor EL" or "Cremofor ELP" (polyoxyethylene-glycerol-trihydroxystearate), or "Tween-80" (polyoxyethylene sorbitan monooleate), or "Solutol HS15" (polyethylene glycol-660 12-hydroxystearate) are used as a co-solubilizing agent. "Collidon 12PF" or "Collidon 17PF" [poly-(1-vinyl-2-pyrrolidone)] are used as a stabilizing agent. Dimethylacetamide or 1-methyl-2-pyrrolidone or "Solufor P" (2-pyrrolidone), or transcutol, or propylene glycol, or ethylene glycol, or glyceroformal, or dimethylsulfoxide are used as a solvent. The proposed injection medicinal formulation comprises additionally phenazone as active substance in the amount 1-10 wt.-%. Invention provides enhancing stability and activity and decreasing toxicity of the medicinal formulation. ^ EFFECT: improved and valuable properties of formulation. ^ 3 cl, 12 ex